Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases.

This phase III study compared the efficacy of the new potent bisphosphonate, ibandronate, with placebo as intravenous (i.v.) therapy in metastatic bone disease due to breast cancer.Clinical TrialClinical Trial, Phase IIIJournal ArticleMulticenter StudyRandomized Controlled TrialResearch Support, Non-U.S. Gov't